Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics Inc.) is an adeno-associated virus vector-based gene therapy indicated for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.
If you have a Hayes login, click here to view the full report on the Knowledge Center.